Gemphire Therapeutics Profile

7.28
USD 0.03  0.41%
91%
64%

Acquisition by Steven Gullans of 50000 shares of Gemphire Therapeutics subject to Rule 16b-3

Gemphire Therapeutics insider trading alert for grant of employee stock option (right to buy) by Steven Gullans, President & CEO, on May 24, 2018. This event was filed by Gemphire Therapeutics Inc with SEC on 2018-05-24. Statement of changes in beneficial ownership - SEC Form 4. Steven Gullans is currently serves as interim president interim ceo, director of Gemphire Therapeutics [view details]   

Gemphire Therapeutics Summary

Gemphire Therapeutics (GEMP) is traded on NASDAQ General Markets in USA. It is located in MICHIGAN, U.S.A and employs 17 people. Gemphire Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Micro-Cap' category with current market capitalization of 92.79 M. Gemphire Therapeutics conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 14.23 M outstanding shares of which 577.3 K shares are currently shorted by private and institutional investors with about 16.0 trading days to cover. Gemphire Therapeutics Inc. currently holds about 18.47 M in cash with (26.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.3.
Check Gemphire Therapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 7.28HorizonTargetOdds Above 7.28
90.41%30 days 7.28 9.51%
Based on normal probability distribution, the odds of Gemphire Therapeutics to move above current price in 30 days from now is about 9.51% (This Gemphire Therapeutics probability density function shows the probability of Gemphire Therapeutics Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Cormorant Asset Management LlcCommon Shares1 M6.8 M
Northpointe Capital LlcCommon Shares779.1 K5.1 M
View Gemphire Therapeutics Diagnostics

Selected Gemphire Therapeutics Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Gemphire Therapeutics Against Markets

Risk Adjusted
Performance Score (0 to 100)
13 
Chance of
Financial Distress (0 to 100%)
14 
Equity ratings for Gemphire Therapeutics are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis . The company was founded in 2008 and is headquartered in Livonia, Michigan. Gemphire Therapeutics operates under Biotechnology classification in USA and traded on NASDAQ General Markets. It employs 17 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameGemphire Therapeutics
President CEOMina SoochView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
LocationMICHIGAN, U.S.A
Business Address17199 North Laurel Park Drive
ExchangeNASDAQ General Markets
CUSIP36870A108
SectorHealthcare
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.gemphire.com
Contact Number734 245 1700
CurrencyUSD - US Dollar

Did you try this?

Run Portfolio Anywhere Now
   

Portfolio Anywhere

Track or share privately all of your investments from the convenience of any device
All  Next Launch Portfolio Anywhere

Recommendations

Gemphire Therapeutics Analyst Recommendations
Target PriceAdvice# of Analysts
24.5Strong Buy4Odds
Gemphire Therapeutics current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Gemphire Therapeutics Analyst Advice  

Earnings

Gemphire Therapeutics Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.72March 21, 2018
Gemphire Therapeutics normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Directors

Gemphire Therapeutics Corporate Directors
Kenneth Kousky Independent Director
Andrew Sassine Independent Director, MBA
Pedro Lichtinger Independent Director, MBA
Please also check Risk vs Return Analysis. Please also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. drill down to check world indexes.